Drug intelligence / Profile preview

HTU-PA

Development stage: Unknown
Lead developer: Global BioTech
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

HTU-PA is a recombinant human tissue-type plasminogen activator (rt-PA) developed by Global Biotech for the treatment of acute ischemic stroke. As a thrombolytic agent, it functions by catalyzing the conversion of the zymogen plasminogen into the active enzyme plasmin. Plasmin subsequently degrades fibrin, the primary protein component of blood clots, thereby facilitating the dissolution of thrombi and restoring blood flow to ischemic brain tissue. The drug was primarily evaluated in Phase 1/2 clinical trials to establish its safety, pharmacokinetic profile, and optimal dosing in patients presenting with acute ischemic stroke within the therapeutic window.

Other names: recombinant human plasminogen activatorrecombinant human tissue-type plasminogen activatorrt-PA

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on HTU-PA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTU-PA.

Explore the full profile